Drug Class Detail

Drug Class EGFR Antibody

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
SYM004 Symphogen EGFR Antibody 27 Symphogen (Sym004) is comprised of two antibodies that bind EGFR and prevent ligand binding, which may prevent downstream signaling and result in decreased tumor cell proliferation (NCI Drug Dictionary).
EMB-01 EMB01|FIT-013a EGFR Antibody 27 MET Antibody 13 Limited information is currently available on EMB-01, a putative bispecific antibody against EGFR and cMET (Feb, 2019).
ABBV-321 EGFR Antibody 27 ABBV-321 is an antibody-drug conjugate consisting of a monoclonal EGFR antibody and the cytotoxic agent, pyrrolobenzodiazepine (NCI Drug Dictionary).
AFM24 EGFR Antibody 27 AFM24 is a bispecific antibody against EGFR and CD16A, which may result in an anti-tumor immune response, specifically, natural killer cells targeting tumor cells that express Egfr (J Clin Oncol 35, 2017 (suppl; abstr e14001)).
JNJ-61186372 EGFR Antibody 27 MET Antibody 13 JNJ-61186372 is a bi-specific antibody that targets EGFR and MET, resulting in inhibition of downstream signaling and potentially leading to decreased growth of EGFR and/or MET-expressing tumors (PMID: 27216193).
ABBV-221 Losatuxizumab vedotin EGFR Antibody 27 ABBV-221 (Losatuxizumab vedotin) is an antibody-drug conjugate that consists of a monoclonal EGFR antibody and a cytotoxic molecule, MMAE, which demonstrates anti-tumor activity against EGFR-expressing tumors (PMID: 29483208).
ME22S EGFR Antibody 27 MET Antibody 13 ME22S is a bispecific antibody that targets EGFR and MET, which results in decreased tumor cell proliferation and migration (PMID: 26812910).
GA201 RG7160 EGFR Antibody 27 GA201 (RG7160) is a humanized antibody directed against EGFR, which prevents ligand binding and dimerization, resulting in decreased EGFR signaling and increased immune response toward EGFR-expressing tumor cells (PMID: 23209031).
SYN004 EGFR Antibody 27 SYN004 is a monoclonal antibody that binds to and inhibits EGFR signaling, leading to potential anti-tumor activity (NCI Drug Dictionary).
Duligotuzumab MEHD7945A EGFR Antibody 27 HER3 (ERBB3) Antibody 13 Duligotuzumab (MEHD7945A) is a two-in-one antibody that inhibits both ERBB3 (HER3) and EGFR signaling, resulting in greater efficacy than monospecific HER antibodies against multiple tumor models (PMID: 22014573).
MM-151 EGFR Antibody 27 MM-151 is a combination of three human monoclonal antibodies targeting distinct, non-overlapping epitopes of epidermal growth factor receptor (EGFR), thereby preventing the binding of ligands and inhibiting EGFR-ERK-mediated signaling (NCI Drug Dictionary).
AVID100 EGFR Antibody 27 AVID100 is an antibody-drug conjugate comprising an EGFR-targeted antibody linked to a cytotoxic drug, which potentially results in decreased growth of EGFR-expressing tumors (Eur J Cancer, Dec 2016, Vol 69, S147).
MCLA-158 EGFR Antibody 27 MCLA-158 is a bispecific antibody that targets EGFR and LGR5, potentially resulting in decreased tumor growth (Cancer Res July 1 2017 (77) (13 Supplement) 32).
EGFRBi-armed autologous activated T cells EGFR Antibody 27 EGFRBi-armed autologous activated T cells are autologous T-cells that have been "armed" with a bispecific antibody that binds EGFR and CD3, potentially enhancing T-cell mediated response to EGFR-expressing cells upon antibody binding (NCI Drug Dictionary).
ABT-806 EGFR Antibody 27 ABT-806 is a monoclonal antibody that binds to the epitope of EGFR vIII and amplified EGFR, but not wild-type EGFR, and may result in anti-tumor activity (PMID: 25731184).
Nimotuzumab Theraloc EGFR Antibody 27 Nimotuzumab is a humanized anti-EGFR antibody that blocks EGFR signaling, resulting in anti-tumor activity (PMID: 25842083).
CT16 EGFR Antibody 27 NOTCH2 Antibody 3 NOTCH3 Antibody 2 CT16 is an antibody that targets both EGFR and NOTCH2/3, resulting in decreased ligand binding and downstream signaling, and potentially leading to decreased tumor growth and increased sensitivity to radiotherapy (PMID: 28275151).
AMG 596 AMG596|AMG-596 EGFR Antibody 27 AMG 596 is a bispecific antibody that targets CD3 on T-cells and the Egfr variant, EGFRvIII, expressed by tumor cells (NCI Drug Dictionary).
LY3164530 EGFR Antibody 27 MET Antibody 13 LY3164530 is a bispecific antibody that targets EGFR and c-Met and inhibits activation of downstream signaling, resulting in decreased proliferation of EGFR and c-Met over expressing tumor cells (NCI Drug Dictionary).
Panitumumab Vectibix ABX-EGF EGFR Antibody 27 Vectibix (panitumumab) is a monoclonal antibody directed against EGFR, which inhibits cell proliferation and induces apoptosis (PMID: 18998757). Vectibix (panitumumab) is FDA approved for metastatic colorectal cancer patients with wild-type KRAS and NRAS (FDA.gov).
GC1118 EGFR Antibody 27 GC1118 is a monoclonal antibody that binds EGFR and prevents ligand binding, potentially resulting in decreased tumor cell proliferation (NCI Drug Dictionary).
Necitumumab Portrazza IMC-11F8 EGFR Antibody 27 Portrazza (necitumumab) is a fully human IgG1 mAb targeting EGFR, leading to the inhibition of downstream targets in the EGFR pathway, and thereby inhibiting cellular proliferation and invasion (PMID: 21154125). Portrazza (necitumumab) is approved for patients with metastatic squamous non-small cell lung cancer (FDA.gov).
HLX07 EGFR Antibody 27 HLX07 is a humanized monoclonal antibody directed against EGFR, which was demonstarted to have increased affinty for Egfr as compared to cetuximab (JCO.2017.35.15_suppl.e14078).
Depatuxizumab mafodotin ABT-414|depatux-m EGFR Antibody 27 Depatuxizumab mafodotin (ABT-414) is an antibody-drug conjugate comprising an EGFR-targeted antibody linked to an anti-microtubule drug, which delivers the cytotoxic agent to EGFR-expressing cells, potentially resulting in increased tumor cell death and decreased growth of EGFR-overexpressing tumors (PMID: 26846818, PMID: 29075855).
ER2 EGFR Antibody 27 ER2 is a human monoclonal antibody directed against EGFR, which leads to decreased EGFR signaling and may result in reduced tumor growth (PMID: 27040853).
Cetuximab Erbitux EGFR Antibody 27 Erbitux (cetuximab) is a monoclonal antibody directed against EGFR, which inhibits signal transduction and cell proliferation (PMID: 28695301). Erbitux (cetuximab) is FDA approved for use in head and neck squamous cell carcinoma and KRAS wild-type, EGFR positive colorectal cancer (FDA.gov).
RM-1929 EGFR Antibody 27 RM-1929 is comprised of the EGFR antibody cetuximab conjugated to the dye IR700, which binds to EGFR-expressing cells and disrupts the cell membrane upon exposure to near-infared light (NCI Drug Dictionary).
Molecular Profile Protein Effect Treatment Approaches